GW Pharmaceuticals plc (NASDAQ:GWPH) – Research analysts at Cantor Fitzgerald dropped their FY2020 EPS estimates for GW Pharmaceuticals in a research report issued on Wednesday, November 4th. Cantor Fitzgerald analyst C. Duncan now forecasts that the biopharmaceutical company will post earnings per share of ($2.16) for the year, down from their prior forecast of ($0.08). Cantor Fitzgerald currently has a “Overweight” rating and a $165.00 target price on the stock. Cantor Fitzgerald also issued estimates for GW Pharmaceuticals’ FY2021 earnings at $6.12 EPS.
Several other equities analysts have also commented on the company. Bank of America reissued a “buy” rating and issued a $234.00 target price on shares of GW Pharmaceuticals in a report on Friday, August 7th. Guggenheim dropped their price objective on GW Pharmaceuticals from $160.00 to $155.00 and set a “buy” rating on the stock in a report on Monday, August 10th. TheStreet lowered GW Pharmaceuticals from a “c-” rating to a “d+” rating in a report on Tuesday, September 1st. BidaskClub lowered GW Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 26th. Finally, The Goldman Sachs Group set a $271.00 price objective on GW Pharmaceuticals and gave the stock an “in-line” rating in a report on Friday, August 7th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and ten have given a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $180.69.
GW Pharmaceuticals (NASDAQ:GWPH) last posted its earnings results on Tuesday, November 3rd. The biopharmaceutical company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.63) by $0.27. The firm had revenue of $137.10 million for the quarter, compared to analyst estimates of $97.66 million. GW Pharmaceuticals had a negative return on equity of 7.50% and a negative net margin of 11.05%. GW Pharmaceuticals’s revenue for the quarter was up 50.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.04) earnings per share.
A number of large investors have recently made changes to their positions in the stock. Laidlaw Wealth Management LLC acquired a new stake in GW Pharmaceuticals in the second quarter valued at about $32,000. Federated Hermes Inc. lifted its position in GW Pharmaceuticals by 9.3% in the second quarter. Federated Hermes Inc. now owns 823,400 shares of the biopharmaceutical company’s stock valued at $101,048,000 after purchasing an additional 69,968 shares during the period. Point72 Asset Management L.P. lifted its position in GW Pharmaceuticals by 583.8% in the second quarter. Point72 Asset Management L.P. now owns 514,806 shares of the biopharmaceutical company’s stock valued at $63,177,000 after purchasing an additional 439,523 shares during the period. Bank of New York Mellon Corp lifted its position in GW Pharmaceuticals by 47.2% in the second quarter. Bank of New York Mellon Corp now owns 372,528 shares of the biopharmaceutical company’s stock valued at $45,715,000 after purchasing an additional 119,421 shares during the period. Finally, Bellevue Group AG lifted its position in GW Pharmaceuticals by 39.3% in the second quarter. Bellevue Group AG now owns 349,566 shares of the biopharmaceutical company’s stock valued at $42,899,000 after purchasing an additional 98,600 shares during the period. Hedge funds and other institutional investors own 80.52% of the company’s stock.
In other news, insider Douglas B. Snyder sold 24,000 shares of the stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $9.40, for a total transaction of $225,600.00. Following the completion of the sale, the insider now owns 122,364 shares in the company, valued at $1,150,221.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Volker Knappertz sold 6,000 shares of the stock in a transaction dated Wednesday, November 4th. The stock was sold at an average price of $9.17, for a total transaction of $55,020.00. Following the sale, the insider now owns 41,940 shares of the company’s stock, valued at approximately $384,589.80. The disclosure for this sale can be found here. Insiders have sold 351,552 shares of company stock valued at $3,002,341 in the last quarter. Insiders own 3.10% of the company’s stock.
About GW Pharmaceuticals
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.
See Also: dividend yield calculator
Receive News & Ratings for GW Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.